16.05.2023 17:40:55
|
EQS-News: HAEMATO AG: Dividend of EUR 1.20
EQS-News: HAEMATO AG
/ Key word(s): Dividend
Dividend of EUR 1.20 Berlin, May 16, 2023 - At today's balance sheet meeting, the annual financial statements 2022 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.20 per dividend-bearing share to the Annual General Meeting taking place in presence on July 18th 2023. About HAEMATO: HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on trading in high-priced specialty pharmaceutical drugs (with a therapeutic focus on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at https://haemato.de. .Contact: HAEMATO AG, Investor RelationsTelefon: +49 (0)30 897 30 86 70 ir@haemato.ag
16.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | HAEMATO AG |
Lilienthalstraße 5c | |
12529 Schönefeld | |
Germany | |
Phone: | +49 (0)30 897 30 86 70 |
Fax: | +49 (0)30 897 30 86 79 |
E-mail: | ir@haemato.ag |
Internet: | www.haemato.ag |
ISIN: | DE000A289VV1 |
WKN: | A289VV |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange |
EQS News ID: | 1634693 |
End of News | EQS News Service |
|
1634693 16.05.2023 CET/CEST
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu HAEMATO AGmehr Nachrichten
Keine Nachrichten verfügbar. |